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Abstract
Introduction—Head and neck squamous cell carcinomas (HNSSCs) are one of the leading 
causes of cancer-associated death worldwide. Although certain behavioral risk factors are well 
recognized as tumor promoting, there is very little known about the presence of predisposing 
germline mutations in HNSCC patients.
Methods—In this study, we analyzed 121 individuals with HNSCCs collected at our institution 
for germline alterations in the newly identified cancer susceptibility gene RAD51C.
Results—Sequencing of all exons and the adjacent introns revealed five distinct heterozygous 
sequence deviations in RAD51C in seven patients (5.8%). A female patient without any other risk 
factors carried a germline mutation that disrupted the canonical splice acceptor site of exon 5 (c.
706-2A>G).
Conclusions—As there are only a few publications in the literature identifying germline 
mutations in head and neck cancer patients, our results provide the first indication that paralogs of 
RAD51, recently implemented in breast and ovarian cancers, might also be candidates for genetic 
risk factors in sporadic squamous cell carcinomas of the head and neck.
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Introduction
Six percent of all human malignant tumors worldwide are squamous cell carcinomas of the 
head and neck region (HNSCCs) (1). In Europe, the consumption of alcohol and nicotine are 
the main behavioral risk factors to develop HNSCC (2, 3), however infections with the 
oncogenic human papilloma virus (HPV) −16 or −18 strains also contribute significantly to 
tumorigenesis and incidence of HNSCCs (4). Genetic factors might also play a role in the 
development of HNSCCs at a relatively early age and especially in the absence of any 
known tumorigenic trigger, however almost all changes described were somatic mutations 
present in the tumor cells (5–13).
Fanconi anemia (FA) is a rare inherited recessive disorder usually diagnosed around 10 
years of age, where patients without behavioral risk factors frequently develop HNSCCs in 
their early adulthood (14–17). The genetic causes for FA are autosomal or X-chromosomal 
germline defects in at least 16 different genes involved in the repair of DNA crosslinks at 
stalled replication forks (18–22). Cells with defects in the FA pathway show spontaneous 
chromosomal instability and a characteristic hypersensitivity to DNA crosslinking agents 
such as mitomycin C (MMC) (23). Clinically, FA patients are characterized by congenital 
abnormalities, progressive bone marrow failure, and the predisposition to leukemia and 
epithelial cancers (15). Remarkably, about 50% of FA patients without stem cell 
transplantation and nearly 100% of transplanted FA patients develop a squamous cell 
carcinoma of the head and neck until 45 years of age (17).
During the last six years, heterozygous germline and also acquired defects of FA genes were 
identified in patients with sporadic epithelial cancers such as breast (24–26), ovarian (27, 
28), cervical (29), lung (30), pancreatic (31, 32) or testicular cancer (33). Since genetic 
instability is also seen as a major force for driving head and neck cancer tumorigenesis (34), 
heterozygous germline defects in genes of the FA pathway could also be a predisposing 
genetic condition for the development of HNSCC. Indeed, initial work identified defects in 
the FA pathway in sporadic HNSCCs, such as downregulation of several FA genes in 
sporadic HNSCCs (35), inactivating promoter methylation in FANCB (36) and defective 
FANCD2 foci formation after stimulation (37).
Recently, we identified RAD51C (RAD51L2), putatively designated as FANCO (38), as a 
human cancer susceptibility gene for inherited breast and ovarian malignancies (39). 
RAD51C is one of five paralogues (RAD51B, RAD51C, RAD51D, XRCC2, XRCC3) of the 
highly conserved RAD51 recombinase that plays a central role in the homologous repair 
(HR) of DNA double strand breaks (DSBs) in mammalian cells, mediating homologous 
DNA pairing and strand exchange (40, 41). In cells that are defective in any of the 
paralogues, the formation of RAD51 foci is strongly reduced in response to DNA damage 
and correlates with decreased HR efficiency, increased genomic instability and a higher 
incidence of chromosomal abnormalities (41, 42).
In order to determine whether RAD51C germline mutations are also a predisposing 
condition for the development of HNSCC, peripheral blood (PB) DNA from 121 patients 
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(male: 97; 80.2%, female: 24; 19.8%) diagnosed with sporadic HNSCCs at our institution 
was analyzed for RAD51C mutations by direct sequencing (38, 39).
Materials and Methods
Patients
PB samples were collected from 121 consecutive patients of the Department of 
Otorhinolaryngology (Heinrich-Heine University, Düsseldorf, Germany) with histologically 
confirmed HNSCCs, including all sites (55 oropharynx, 20 hypopharynx, 27 larynx, 7 Sinus, 
2 scalp, 10 CUP (carcinoma of unknown primary)) and stages (cis, T1–4, N0–3, M0/1) of 
disease after obtaining informed consent. Research was carried out in compliance with the 
Helsinki Declaration. This study was reviewed and approved by the ethics committee of the 
University of Düsseldorf (Study No. 3515).
HPV Status
For immunohistochemical staining of p16/INK4a, 2-µm sections were stained using the 
CINtec PLUS kit (mtm Laboratories, Heidelberg, Germany) according to the manufacturer’s 
instructions as described previously (43).
Sequencing of all 9 exons of the RAD51C gene
DNA was isolated from PB leukocytes according to the manufacturer’s recommendation 
(Genomic DNA purification kit, Gentra Biosystems, Minneapolis, USA). Each of the 9 
exons of the RAD51C gene was amplified in a standard PCR reaction using Qiagen 
Mastermix (Qiagen, Hilden, Germany). Primers and PCR conditions are shown in Table 1. 
The PCR products were purified (Qiaquick PCR Purification Kit, Qiagen), and mixed with 
ABI PRISM BigDye Terminator sequencing kit (Applied Biosystems, Weiterstadt, 
Germany) and primers for sense direction or for antisense direction (Table 1). After the 
sequencing reaction (25 cycles of 15 sec at 96°C and 4 min at 60°C), the products were 
purified (DyeEx 2.0 Spin Kit, Qiagen) and analyzed with an automated sequencer (ABI 310, 
Applied Biosystems). Positive samples underwent confirmation by repeated analysis.
Results
In total, we identified five heterozygous germline alterations in seven (3 females, 4 males) 
out of 121 individuals. All sequence changes were single nucleotide alterations (Table 2). 
The mutation c.706-2A>G was located in the canonical splice acceptor dinucleotide of 
intron 4 in the germline DNA from a female without any behavioral risk factors and is 
clearly pathogenic as it leads to a loss of exon 5 in the mRNA resulting in an in-frame 
deletion of 44 amino acids, pV236del44, in the RAD51C protein. This germline mutation 
was previously described by Walsh et al. 2011 (44) in a 70-year old stage IV ovarian cancer 
patient with loss-of-heterozygosity (LOH) in the tumor tissue and by Loveday et al. 2012 
(45) in a 56-year old female with ovarian cancer. Four missense alterations identified in six 
patients were located in the exons 1 (1×, c.7G>A, p.G3R), 2 (2×, c.376G>A, p.A126T), 5 
(1×, c.790G>A, p.G264S) and 6 (2×, c.859A>G, p.287A), respectively.
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Four of the HNSCCs were located at the larynx, two in the oropharynx and one in the 
hypopharynx. The two patients with laryngeal carcinomas developed additional 
malignancies: one experienced an oropharyngeal carcinoma and one was diagnosed with 
bronchial carcinoma (Table 2). As overexpression of the p16 protein can be used as a 
surrogate marker for HPV infection in tissues (45), we analyzed the available tumor tissue 
samples of the seven patients by immunohistochemistry: samples from three patients stained 
p16 positive, suggesting HPV infections, and three samples were negative. From one patient 
(#5), tumor tissue was not available. Two patients had a combined history of regular alcohol 
uptake and cigarettes consumption, two other individuals smoke cigarettes, while three 
patients were not exposed to any of these drugs (Table 2).
Discussion
We identified five RAD51C germline alterations in seven patients with sporadic HNSCC, 
representing 5.8% of all analyzed 121 individuals. All patients who carried RAD51C 
alterations had tumors that originate from the mucus membrane as most frequent carcinoma 
type in our series. Four of the five changes were missense alterations that we previously 
reported in individuals from German pedigrees with breast and ovarian cancers (39). The 
functional characterizations of these four RAD51C alterations in this earlier study revealed 
that expression of c.7G>A (patient 1) and c.376G>A (patients 2 and 3) mutated RAD51C 
cDNAs transferred via retroviral vectors in Rad51c−/− chicken DT40 cells and in human 
RAD51C-mutated fibroblasts was associated with normal cellular survival and normal 
RAD51 foci formation in response to MMC exposure, respectively (39). In contrast, 
expression of the c.790G>A (patient 5) and the c.859A>G (patient 6 and 7) RAD51C 
alterations showed clearly reduced survival of RAD51c−/− DT40 cells upon MMC challenge 
albeit normal RAD51 foci formation (39). As the latter two missense alterations were 
associated with impaired cellular viability in response to DNA cross-linking agent MMC 
(39), we had hypothesized that these two alterations should therefore be associated with an 
increased cancer risk. However, comparative analysis with 2912 representative control 
individuals of the German population revealed that only the c.790G>A alteration in 
RAD51C was associated with an increased risk of 3.44 (confidence interval 1.51–7.8, 
p<0.005) for developing gynecological cancers (39). A similar association of RAD51C c.
790G>A mutation with an increased cancer risk was also confirmed in the British study by 
Loveday et al. (45). The fifth RAD51C germline alteration in our patient population was a 
splice acceptor mutation, c.706-2A>G, that disrupts the canonical AG splice acceptor site 
and thereby leads to a loss of exon 5 in the transcript and a frameshift in the open reading 
frame with premature protein truncation. This mutation was previously detected in two 
individuals with ovarian cancer and classified in both publications as detrimental (44, 45).
Strikingly, three out of the seven HNSCC patients with germline alterations in RAD51C 
were females (43%), while only 20% of all patients in our patient cohort were women. All 
three women did not have any history of tobacco and alcohol consumption as typical 
triggers for the development of HNSCCs. The tumor in the patient 3 with the functionally 
normal c.376G>A alteration (39) was classified as HPV positive, thus providing an 
explanation for the HNSCC development in this individual. Importantly, the absence of any 
risk factor in patient 4 (c.706-2A>G) with a HPV16/18 negative tumor and the development 
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of an independent lung cancer in patient 5 (c.790G>A) strongly indicated an underlying 
genetic cancer susceptibility in these two women, likely due to the RAD51C germline 
mutations. In contrast, all four male patients had a history of smoking cigarettes. Two also 
consumed alcohol and their tumors were classified as HPV positive. Therefore, the risk 
factor profiles in these four individuals were similar to those of patients without any 
alterations in RAD51C and characteristic for HNSCC patients. Hence, an association of the 
development of HNSCCs with germline changes in RAD51C was not evident in the four 
male patients.
The most important risk factors for HNSCCs in the western hemisphere are behavioral 
factors, predominantly chronic exposure to tobacco and/or alcohol and infection with HPV 
(4). HNSCC cancer carcinogenesis has been linked to abnormalities in DNA repair, 
apoptosis, carcinogen metabolism and cell cycle control (1) and somatic changes in 
associated genes in HNSCC tissues were described by several groups (5, 7, 8, 47–49). 
However, specific germline mutations predisposing to HNSCCs have only been identified in 
P53 and INK4a/p16 that are associated with a wide variety of human cancers (50, 51). Here, 
we provide first evidence that germline alterations in the established cancer susceptibility 
gene RAD51C (38, 39, 44, 45) are also present in HNSCC patients. These alterations in the 
RAD51C protein in at least 4 out of 121 patients (3%) are associated with reduced (patients 
5, 6 and 7) (39) or absent (patient 4, c.706-2A>G) function, thus suggesting that germline 
mutations in genes of the FA pathway could contribute to the development of HNSCCs. 
Here, further studies of analyzing HNSCC patients for germline mutations in FA-associated 
genes will provide further insides whether the ’common disease, rare allele’ hypothesis (52) 
might also apply to a subset of HNSCC patients at relatively young age and without known 
risk factors.
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Table 1
Exon Forward 5’ to 3’ Reverse 3’ to 5’ Tm (°C) Size (bp)
1 AAATGGGATTTTGGGGAATC GTAAACATGGACGTGGGAGG TD* 471
2 AAAATTAAATGGTTGATAGAATGTTGC TCAAGAAGGGATAATGAAGTAACAC 65 583
3 GACATTTCTGTTGCCTTGGG GCTGTGGCATTTCTCATTTTG 65 472
4 TTTTGCTATAATTTGTCATCTTTCAG TTGTAGGTCAAGGAAGGAAGAGA 60 413
5 TTACTGTTCCAGGCATTGGG TGGAAACCAACCAAACGTAAC 65 430
6 GTGCATGCCACCATGTCT TGTGTCTGGCCACTCAATAAA 68 398
7 GAATAATGATTTGCAGTATTTCC CAGACAAGGCAACAAAAGTGTC 65 400
8 CATACGGGTAATTTGAAGGGTG TTTGGGGACAATGTTCTAAGC 65 384
9 CGCCTGGCCCTAGAATAAA GGCCACATGAGATCAGCTTT 65 491
*
Primer sequences used to amplify and sequence RAD51C, with annealing temperature (Tm) and amplicon size (TD – touchdown PCR, indicates 
that DMSO was added to a final concentration of 10%).
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